ClinicalTrials.gov

History of Changes for Study: NCT03725852
A Clinical Study to Test How Effective and Safe GLPG1205 is for Patients With Idiopathic Pulmonary Fibrosis (IPF) (PINTA)
Latest version (submitted August 18, 2021) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 October 29, 2018 None (earliest Version on record)
2 December 19, 2018 Study Status and Contacts/Locations
3 January 17, 2019 Study Status and Contacts/Locations
4 February 13, 2019 Study Status and Contacts/Locations
5 March 5, 2019 Outcome Measures, Study Status, Contacts/Locations and Eligibility
6 April 1, 2019 Study Status and Contacts/Locations
7 April 29, 2019 Contacts/Locations and Study Status
8 May 23, 2019 Study Status and Contacts/Locations
9 June 21, 2019 Study Status and Contacts/Locations
10 August 14, 2019 Study Status and Contacts/Locations
11 October 1, 2019 Study Status and Contacts/Locations
12 November 20, 2019 Study Status and Contacts/Locations
13 December 17, 2019 Study Status and Contacts/Locations
14 January 14, 2020 Recruitment Status, Study Status, Contacts/Locations and Study Design
15 August 17, 2020 Study Status
16 September 10, 2020 Recruitment Status, Study Status
Show
Results Submission Events
17 August 18, 2021 Outcome Measures, Study Status, Arms and Interventions, Document Section, Results, IPDSharing, References, Eligibility, Study Design, Study Description and Study Identification
Comparison Format:

Scroll up to access the controls

Study NCT03725852
Submitted Date:  October 29, 2018 (v1)

Open or close this module Study Identification
Unique Protocol ID: GLPG1205-CL-220
Brief Title: A Clinical Study to Test How Effective and Safe GLPG1205 is for Patients With Idiopathic Pulmonary Fibrosis (IPF) (PINTA)
Official Title: A Phase II Randomized, Double-blind, Placebo-controlled, 26-week Study to Evaluate the Efficacy, Safety and Tolerability of GLPG1205 in Subjects With Idiopathic Pulmonary Fibrosis
Secondary IDs: 2017-004302-18 [EudraCT Number]
Open or close this module Study Status
Record Verification: October 2018
Overall Status: Recruiting
Study Start: September 27, 2018
Primary Completion: April 25, 2020 [Anticipated]
Study Completion: May 16, 2020 [Anticipated]
First Submitted: June 8, 2018
First Submitted that
Met QC Criteria:
October 29, 2018
First Posted: October 31, 2018 [Actual]
Last Update Submitted that
Met QC Criteria:
October 29, 2018
Last Update Posted: October 31, 2018 [Actual]
Open or close this module Sponsor/Collaborators
Sponsor: Galapagos NV
Responsible Party: Sponsor
Collaborators:
Open or close this module Oversight
U.S. FDA-regulated Drug: No
U.S. FDA-regulated Device: No
Data Monitoring: Yes
Open or close this module Study Description
Brief Summary: This is a randomized, double-blind, parallel group, placebo-controlled, multicenter, exploratory Phase II study including subjects with Idiopathic Pulmonary Fibrosis (IPF), investigating GLPG1205 of top of local standard of care (defined as receiving nintedanib, pirfenidone, or neither nintedanib or pirfenidone).
Detailed Description:
Open or close this module Conditions
Conditions: Idiopathic Pulmonary Fibrosis
Keywords:
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 2
Interventional Study Model: Parallel Assignment
Number of Arms: 2
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation: Randomized
Enrollment: 60 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Experimental: GLPG1205 dose A
GLPG1205 will be taken as 2 capsules, once daily (q.d.), administered for 26 weeks on top of local standard of care.
Drug: GLPG1205
GLPG1205 will be provided as an oral hard gelatin capsule.
Placebo Comparator: Placebo
Matching placebo once daily (q.d.) administered for 26 weeks on top of local standard of care.
Drug: Placebo
matching placebo will be provided as an oral hard gelatin capsule.
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Change from baseline in forced vital capacity (FVC) (mL) over 26 weeks compared to placebo.
[ Time Frame: From Day 1 to Week 26 ]

To evaluate the efficacy of GLPG1205 treatment in subjects with IPF on pulmonary function as evaluated by FVC compared to placebo over 26 weeks.
Secondary Outcome Measures:
1. The number of incidents of Treatment-Emergent Adverse Events (TEAEs), Unlisted (Unexpected) Adverse Events, Serious Adverse Events (SAEs), and discontinuations due to Adverse Events (AEs).
[ Time Frame: From Day 1 to Week 26 ]

To evaluate the safety and tolerability of GLPG1205 treatment compared to placebo over 26 weeks.
2. Time to any of major events (whichever occurs first) defined as below:
[ Time Frame: From Day 1 through study completion up to Week 30 ]

To evaluate the impact of GLPG1205 treatment compared to placebo on time to any major events (whichever occurs first) defined as:

  • Respiratory-related mortality
  • Hospitalization (all-cause and respiratory related)
  • Need for placement on a lung transplant list
3. Change from baseline in functional exercise capacity, assessed by the six-minute walk test (6MWT) at Week 26.
[ Time Frame: From Day 1 to Week 26 ]

To evaluate the changes from baseline in functional exercise capacity measured by the 6MWT, in IPF subjects treated with GLPG1205 compared to placebo at Week 26.
4. Change from baseline until 26 weeks in quality of life measures, assessed by the St.George's Respiratory Questionnaire (SGRQ) total score and domains and proportion of SGRQ responders.
[ Time Frame: From Day 1 to Week 26 ]

To evaluate the changes in quality of life measures in IPF subjects treated with GLPG1205 compared to placebo over 26 weeks.
5. Concentrations of GLPG1205, nintedanib and pirfenidone.
[ Time Frame: From Day 1 to Week 30 ]

To evaluate the pharmacokinetics (PK) of GLPG1205, nintedanib and pirfenidone in IPF subjects.
Open or close this module Eligibility
Minimum Age: 40 Years
Maximum Age:
Sex: All
Gender Based:
Accepts Healthy Volunteers: No
Criteria:

Inclusion criteria:

Subjects who meet all of the following criteria are eligible for the study:

  • Signed informed consent form (ICF) obtained prior to any study-related procedures and/or assessments performed.
  • Males or females of non-child-bearing potential, aged ≥40 years on the day of signing the ICF.
  • A diagnosis of IPF within 3 years prior to the screening visit as per American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Association (ALAT) guidelines. Subjects receiving local standard of care, defined as nintedanib, pirfenidone, or neither nintedanib or pirfenidone. Also prednisone at steady dose ≤15 mg/day is allowed (stabilized 4 weeks prior to screening and continued without variation of dose or regimen). Supportive care like supplemental oxygen or pulmonary rehabilitation is allowed.
  • Meeting all of the following criteria at screening and during the screening period:
    • FVC ≥50% predicted of normal
    • Disease progression in the last 9 months prior to the screening period and at screening, defined as at least one prescreening FVC value and screening value with a decline of FVC (% predicted or mL), at the investigator's discretion
    • Diffusing capacity for the lungs for carbon monoxide (DLCO) ≥30% predicted of normal (corrected for hemoglobin)
    • Ratio of forced expiratory volume in one second (FEV1) to FVC ≥0.70
  • In a stable condition and suitable for study participation based on the results of a medical history, physical examination, vital signs, 12-lead ECG, and laboratory evaluation. Stable condition is based on the clinical judgment of the investigator, co-morbidities should be treated according to the local applicable guidelines. Concomitant medication for comorbidities should be stabilized from 4 weeks before screening and during the screening period (stable defined as no change of dose or regimen).
  • Able to walk at least 150 meters during the 6MWT at screening; without having a contraindication to perform the 6MWT.

This list only describes the key inclusion criteria.

Exclusion criteria:

Subjects meeting one or more of the following criteria cannot be selected for this study:

  • Known hypersensitivity to any of the investigational medicinal product (IMP) ingredients or a history of a significant allergic reaction to any drug as determined by the investigator (e.g. anaphylaxis requiring hospitalization).
  • History of or a current immunosuppressive condition (e.g. human immunodeficiency virus [HIV] infection, congenital, acquired, medication induced).
  • Positive serology for hepatitis B (surface antigen and core antibody) or C (antibody), or any history of hepatitis from any cause with the exception of hepatitis A.
  • History of malignancy within the past 5 years (except for carcinoma in situ of the uterine cervix, basal cell carcinoma of the skin that has been treated with no evidence of recurrence, and prostate cancer medically managed through active surveillance or watchful waiting, and squamous cell carcinoma of the skin if fully resected).
  • Acute IPF exacerbation within 3 months prior to screening and during the screening period.
  • Lower respiratory tract infection requiring antibiotics within 4 weeks prior to screening and/or during the screening period.
  • Interstitial lung disease associated with known primary diseases (e.g. sarcoidosis, amyloidosis), exposures (e.g. radiation, silica, asbestos, coal dust), and drugs (e.g. amiodarone).
  • History of lung volume reduction surgery or lung transplant.
  • Unstable cardiovascular, pulmonary (other than IPF) or other disease within 6 months prior to screening or during the screening period (e.g. coronary heart disease, heart failure, stroke).
  • Subject participating in a drug, device or biologic investigational research study, concurrently with the current study, or within 5-halflives of the agent (or within 8 weeks when half-life is unknown) prior to screening, or prior participation in an investigational drug antibody study within 6 months prior to screening.

This list only describes the key exclusion criteria.

Open or close this module Contacts/Locations
Central Contact Person: Evelyn Fox
Telephone: 0032 15 34 29 00
Email: evelyn.fox@glpg.com
Study Officials: Christian Seemayer, MD
Study Director
Galapagos NV
Locations: Slovakia
ZAPA JJ s.r.o.
[Recruiting]
Levice, Slovakia, 934 01
Pľúcna Ambulancia Hrebenár, s.r.o.
[Recruiting]
Spišská Nová Ves, Slovakia, 05201
Open or close this module IPDSharing
Plan to Share IPD:
Open or close this module References
Citations:
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services